Laboratory Corporation of America Holdings

Other

Monogram Biosciences, Inc.

Jeff Sperinde

Michael R Bates

John William Winslow

Gordon Parry

Gundo Diedrich

Ali Mukherjee

Stephen J Williams

Xueguang Jin

Jennifer W Cook

Laurie Goodman

Gerald J Wallweber

Weidong Huang

Mojgan Haddad

Jodi Weidler

Sharat Singh

Hossein Salimi-Moosavi

Colombe Chappey

Liching Cao

Sean C Moore

Stephen John Williams

Michael Bates

The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.

Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients

The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.

Methods of determining patient response by measurement of HER-3

In certain aspects, the present invention provides methods for determining whether a Her-2 positive cancer is likely to respond to treatment with a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a slow disease progression. In other aspects, the present invention is drawn to methods for determining whether a subject with a Her-2 positive cancer is unlikely to respond to treatment with at least one chemotherapeutic agent in addition to a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a fast disease progression.

Her2 diagnostic methods

The disclosure provides methods of making antibodies specific for p95.

Methods of producing antibodies specific for p95

The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex and the presence and/or amount of p95 in a sample. The invention also provides antibodies specific for Her-3.

Methods of determining patient response by measurement of HER-3 and P95

HER-3 antibodies and methods of use

The invention provides methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample. The invention also provides antibodies specific for p95.

Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95

Methods of determining patient response by measurement of Her-3

Methods, compositions and kits are provided for assessing angiogenesis through sensitive, direct detection of activation of endothelial cells at molecular levels. In general, activation of endothelial cells is detected by measuring the levels of cellular components and their protein complexes participating in a specific angiogenesis signaling pathway in endothelial cells. The methods can be used for assessing status of diseases associated with undesirable angiogenesis, such as the likelihood of developing the disease, presence or absence of the disease, prognosis of the disease and the likelihood of response or resistance to a particular anti-angiogenic therapy. The methods can also be used to guide the design of effective therapeutic regimens targeting a specific angiogenic signaling pathway, as well as in conjunction with therapeutic intervention of diseases or conditions associated with undesirable angiogenesis.

Detection of activation of endothelial cells as surrogate marker for angiogenesis

Growing community of inventors

El Granada, CA, United States of America

Jeff Sperinde